Intracorporeal medicaments for photodynamic treatment of disease
New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection. In another preferred embodiment, such medicaments are produced in various formulations including liquid, semisolid, solid or aerosol delivery vehicles.
1. A method of treating human tissue comprising:
applying an intracorporeal medicament comprising at least one halogenated xanthene into or proximate to said human tissue, wherein said halogenated xanthene is disodium 4,5,6,7-Tetrabromoerythrosin; and
illuminating said human tissue with light having a wavelength of between approximately 500 and 600 unm to activate said halogenated xanthene present within or proximate to said tissue.
2. The method of claim 1 wherein said human tissue comprises the skin, the mouth and digestive tract, the urinary and reproductive tracts, the respiratory tract, the circulatory system, the head and neck, the endocrine and lymphoreticular systems, connective tissue, tissue surfaces exposed during surgery, and tissue with microbial, viral, or fungal infection.